Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | July 1, 2020 | News story | Research and Development | COVID-19, coronavirus
COVID-19 vaccines dominate this week’s news cycle, with Vaxart announcing the selection of its lead candidate for COVID-19 by Operation Warp Speed, while China’s military have received approval to use a new vaccine candidate and AstraZeneca has continued to build its manufacturing capacity to deliver its coronavirus vaccine.
In other news, the National Institutes of Health had its funding cut from a research project into bat coronavirus while Gilead has announced that it will charge $2,340 for a 5 day treatment course of remdesivir, a drug that has been proven to reduce the symptoms of COVID-19.
1. NIH ordered to cancel coronavirus research funding by White House, Dr Fauci tells Congress – Published 25/06/20
The National Institutes of Health had its funding cut from a research project into bat coronavirus, according its Director Dr Anthony Fauci.
2. AstraZeneca continues to ramp up COVID-19 vaccine production with new CMO partnership – Published 25/06/20
AstraZeneca has continued to build its manufacturing capacity to deliver its COVID-19 vaccine candidate, developed in partnership with the University of Oxford and currently being tested in human trials across a number of trials across the UK, with its latest partnership signed with Scottish firm Symbiosis Pharmaceutical Services.
3. Vaxart announces its COVID-19 vaccine has been selected by US Operation Warp Speed programme – Published on 29/06/20
Vaxart has announced the selection of its lead vaccine candidate for COVID-19 by Operation Warp Speed, a program to find a vaccine for the US by the end of the year.
4. China’s COVID-19 vaccine candidate approved for military use – Published 29/06/20
China’s military have received approval to use a new vaccine candidate for coronavirus after clinical trials proved it was safe and showed some efficacy.
5. Gilead facing criticism for charging $2,340 for remdesivir – Published on 30/06/20
Gilead has announced that it will charge $2,340 for a 5 day treatment course of remdesivir, a drug that has been proven to reduce the symptoms of COVID-19.
Conor Kavanagh
Related Content
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …
